Mortality, Morbidity and Risk Factors of Liver Retransplantation

• Sponsor: Memorial Bahçelievler Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT04789213
• Collaborator: (none)
• Enrollment: 32
• Location: 1
• Actual Duration (Months): 1.7
• Patients Per Site Per Month: 18.7

Study Details

Study Description

Brief Summary

This study aims to compare the short and long term outcomes of living donor and deceased donor liver retransplantation. Bearing that in mind, the investigators will retrospectively analyze the files of patients whom underwent a liver retransplantation in Memorial Bahcelievler Hospital Organ Transplantation Center.

Condition or Disease	Intervention/Treatment	Phase
Liver Transplant; Complications; Liver Transplant Rejection; Liver Transplant Failure; Liver Diseases; Liver Cirrhosis; Liver Failure; Organ Transplant Failure or Rejection	Other: Liver Transplantation

Study Design

• Study Type: Observational
• Actual Enrollment: 32 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: Comparison of Mortality, Morbidity and Risk Factors in Living- Donor and Deceased-Donor Liver Retransplantation
• Actual Study Start Date: Mar 10, 2021
• Actual Primary Completion Date: Apr 15, 2021
• Actual Study Completion Date: May 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Patients with Living Donor Liver Transplantation	Other: Liver Transplantation; Liver Transplantation
Patients with Deceased Donor Liver Transplantation	Other: Liver Transplantation; Liver Transplantation

Outcome Measures

Primary Outcome Measures

1. Survival ratio [1 minutes]

   Overall graft and patient survival ratio

Secondary Outcome Measures

1. Morbidity [10 minutes]

   Postoperative complications such as septicemia, hepatic artery thrombosis etc.

2. Peri-operative informations [15 minutes]

   Peri-operative informations such as blood loss during surgery

3. Blood Test Results [20 minutes]

   Patients' blood test results specific to liver such as International Normalization Ratio

Eligibility Criteria

Criteria

• Ages Eligible for Study: 0 Months and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Having a liver retransplantation

Exclusion Criteria:

• N/A

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Memorial Bahçelievler Hospital	Istanbul		Turkey	34700

Sponsors and Collaborators

• Memorial Bahçelievler Hospital

Investigators

• Principal Investigator: Kamil Yalçın Polat, Prof, Memorial Bahçelievler Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Kamil Yalçın Polat, Prof.Dr., Memorial Bahçelievler Hospital
• ClinicalTrials.gov Identifier: NCT04789213
• Other Study ID Numbers: MemorialBahcelievler1
• First Posted: Mar 9, 2021
• Last Update Posted: Dec 6, 2021
• Last Verified: Dec 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Liver Diseases; Liver Cirrhosis; Liver Failure

Study Results

No Results Posted as of Dec 6, 2021